Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride can quickly raise estradiol levels by blocking DHT, allowing testosterone to convert to estrogen. Taking finasteride for just a few days can affect blood test results.

A 26-year-old has seen hair regrowth in 4.5 months using oral finasteride, topical minoxidil, and recently RU58841 on the temples. Suggestions include adding weekly microneedling to improve results.

The user is experiencing breast tenderness and lumps after three weeks on 0.5 mg oral finasteride, a common side effect. They also report mild brain fog and fatigue but are less concerned about these symptoms.

A 35-year-old experienced slow but noticeable hair density improvement over 5 months using 0.5 mg oral dutasteride, 2.5 mg oral minoxidil, and 5 mg oral biotin daily. Initial shedding and acne were side effects, but overall satisfaction was reported.

A 23-year-old shared progress pictures after five months on Finasteride, starting with 0.25mg and increasing to 1mg, reporting no side effects and noticeable hair improvement. The user is satisfied with the results and plans to continue the treatment, while others in the conversation discuss dosage, side effects, and alternative treatments.

A 22-year-old user experienced positive hair regrowth after 11 weeks using a spray containing 0.3% finasteride, 7% minoxidil, 2.2% ketoconazole, and 0.2% biotin. They reported initial side effects like scalp tingling and brief testicular pain, which subsided, and are considering switching to finasteride pills and a different minoxidil brand for cost reasons.

The user has been using oral minoxidil 2.5 mg for 9 months and oral finasteride 1 mg for 4 months, along with microneedling, and has noticed more baby hairs and longer eyelashes but no extra overall thickness. They are considering increasing the minoxidil dose but are concerned about safety due to potential side effects.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

A 23-year-old is using 0.25mg Finasteride for hair loss and experiencing increased shedding after initial reduction. Advice given is to wait longer for results, as hair cycles take time to adjust, and consider increasing the dose if no improvement occurs in a few months.

The user experienced hair regrowth using a topical solution containing 5% minoxidil and 0.1% finasteride, despite an initial shedding phase. They reported no side effects and noted significant improvement in hair density, particularly around the crown area.

The user experienced increased hair density and improved hairline definition after 8 months of using 1mg finasteride and 5mg minoxidil (both oral and topical) daily, though the hairline recession hasn't reversed. They noticed fuller eyelashes and increased shedding, but overall hair growth is outpacing the loss.

Hair loss discussion involves PRP (platelet rich plasma) treatment. PRP doesn't stop hair loss, only promotes regrowth; minoxidil is suggested as a better alternative.

The user had a failed hair transplant in 2018, didn't use medication, and experienced severe depression from further hair loss. They started treatment in 2022 with 0.5mg daily finasteride, 2.5mg oral minoxidil, 1ml daily topical minoxidil, and are considering low dose RU58841 and dermarolling.

A 36-year-old man shared his 1.25-year progress using oral finasteride, oral minoxidil, RU58841, microneedling, nizoral, and LLLT for hair regrowth. He is thrilled with the results and considering a hair transplant for increased density.

A man, 35, shows 3-month hair regrowth progress using 0.4mg oral finasteride, 1.0mg minoxidil, topical minoxidil once daily, weekly dermastamping at 1.5mm, and ketoconazole shampoo. He experienced initial worsening, has no side effects, and received positive feedback on his early results.

After 13 years on finasteride, OP is experiencing reduced effectiveness and has started taking 0.5 mg of dutasteride weekly, noticing nipple sensitivity as a side effect. OP plans to increase the dutasteride dosage and retest hormone levels, while others suggest adjusting the dosage or trying different forms of dutasteride.

Increased hair shedding after 3 months of using 0.25mg finasteride, with thin, tapered hairs falling out. The user is concerned about the sudden change in shedding pattern.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

A man in his twenties experiencing hereditary hair loss has been using 5% Minoxidil, a derma roller, Vitamin D3, and recently started Finasteride. He has noticed baby hairs appearing, indicating some regrowth, and is advised to continue the treatment consistently for several months to potentially see significant results.

The user is experiencing significant hair regrowth using 1mg finasteride, 5mg minoxidil, and biotin since April, and may not need a hair transplant. Another user suggests that if a transplant is desired, around 4,000 grafts could provide good coverage.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

The use of PRP to treat hair loss and its potential effectiveness when combined with 5 alpha reductase blockers such as Minoxidil or Finasteride.

A user reported using 1.25mg finasteride daily for 9 months with positive hair growth results and increased libido but slower beard growth. Other users commented on the appearance of straightened vs. natural curly hair and potential hair damage from straightening.

A user shared impressive hair regrowth results after using 1mg finasteride daily for over a year, with minimal side effects. The user also mentioned taking biotin gummies and experiencing periods of shedding followed by thicker hair growth.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A 27-year-old male experienced significant hair regrowth in two months using a daily oral 3-in-1 pill containing 1.1mg finasteride, 5mg minoxidil, and 1mg biotin from LockLab, with no side effects reported. The user also uses a derma-stamp twice a week to promote blood flow and stimulate growth.